Haidy K Giratallah1, Meghan J Chenoweth1, Newton Addo2, Jasjit S Ahluwalia3, Lisa Sanderson Cox4, Caryn Lerman5, Tony P George6, Neal L Benowitz7, Rachel F Tyndale8. 1. Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, CAMH, Toronto, Canada. 2. Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA. 3. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Department of Medicine, Warren Alpert Medical School, Providence, RI, USA. 4. Department of Population Health, University of Kansas Medical School, Kansas City, KS, USA. 5. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA. 6. Campbell Family Mental Health Research Institute, CAMH, Toronto, Canada; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada; Addictions Division, CAMH and Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 7. Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA; Center for Tobacco Control Research and Education, University of California, San Francisco, CA, USA. 8. Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, CAMH, Toronto, Canada; Addictions Division, CAMH and Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address: r.tyndale@utoronto.ca.
Abstract
BACKGROUND: Variation in CYP2A6 activity influences tobacco smoking behaviors and smoking-related health outcomes. Plasma Nicotine Metabolite Ratio (NMR) is a robust phenotypic biomarker of CYP2A6 activity and nicotine clearance. In urine, the NMR has been calculated as a ratio of free trans-3'-hydroxycotinine to free cotinine (NMRF/F), total trans-3'-hydroxycotinine to free cotinine (NMRT/F), or total trans-3'-hydroxycotinine to total cotinine (NMRT/T). We evaluated these three urinary NMR versions relative to plasma NMR and nicotine clearance and elucidated mechanisms of discrepancies among them. METHODS: Baseline plasma and urine biomarker data were available from two smoking cessation clinical trials and one nicotine pharmacokinetic study (total N = 768). NMRs were compared using Pearson correlations, linear regressions and ANOVA analyses. UGT2B10 and UGT2B17 were genotyped. RESULTS: Urinary NMRT/F was the most highly related to plasma NMR (R2 = 0.70, P <2.2e-16) followed by NMRF/F (R2 = 0.68, P <2.2e-16), while NMRT/T was less strongly related (R2 = 0.60, P <2.2e-16); consistent across study, ethnicity, sex, heaviness of smoking, and analyte analysis. Controlling for cotinine glucuronidation, as a phenotype or UGT2B10 genotype, corrected the NMRT/T discordance with plasma NMR (Panova<0.001). Similar findings were obtained for relationships of nicotine clearance with plasma NMR > urinary NMRT/F > NMRF/F > NMRT/T (R2 = 0.41 > 0.37 > 0.35 > 0.25 respectively). CONCLUSION: Urinary NMRT/F followed by NMRF/F are the best urinary alternatives to plasma NMR or nicotine clearance. NMRT/T has the least utility as it is influenced substantially by variation in cotinine glucuronidation. IMPACT: This work highlighted the variation in urinary NMRs, and identified mechanisms for disparities among them, which facilitates their use in predicting smoking-related outcomes.
BACKGROUND: Variation in CYP2A6 activity influences tobacco smoking behaviors and smoking-related health outcomes. Plasma Nicotine Metabolite Ratio (NMR) is a robust phenotypic biomarker of CYP2A6 activity and nicotine clearance. In urine, the NMR has been calculated as a ratio of free trans-3'-hydroxycotinine to free cotinine (NMRF/F), total trans-3'-hydroxycotinine to free cotinine (NMRT/F), or total trans-3'-hydroxycotinine to total cotinine (NMRT/T). We evaluated these three urinary NMR versions relative to plasma NMR and nicotine clearance and elucidated mechanisms of discrepancies among them. METHODS: Baseline plasma and urine biomarker data were available from two smoking cessation clinical trials and one nicotine pharmacokinetic study (total N = 768). NMRs were compared using Pearson correlations, linear regressions and ANOVA analyses. UGT2B10 and UGT2B17 were genotyped. RESULTS: Urinary NMRT/F was the most highly related to plasma NMR (R2 = 0.70, P <2.2e-16) followed by NMRF/F (R2 = 0.68, P <2.2e-16), while NMRT/T was less strongly related (R2 = 0.60, P <2.2e-16); consistent across study, ethnicity, sex, heaviness of smoking, and analyte analysis. Controlling for cotinine glucuronidation, as a phenotype or UGT2B10 genotype, corrected the NMRT/T discordance with plasma NMR (Panova<0.001). Similar findings were obtained for relationships of nicotine clearance with plasma NMR > urinary NMRT/F > NMRF/F > NMRT/T (R2 = 0.41 > 0.37 > 0.35 > 0.25 respectively). CONCLUSION: Urinary NMRT/F followed by NMRF/F are the best urinary alternatives to plasma NMR or nicotine clearance. NMRT/T has the least utility as it is influenced substantially by variation in cotinine glucuronidation. IMPACT: This work highlighted the variation in urinary NMRs, and identified mechanisms for disparities among them, which facilitates their use in predicting smoking-related outcomes.
Authors: Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia Journal: J Natl Cancer Inst Date: 2012-01-25 Impact factor: 13.506
Authors: Sharon E Murphy; Sung-Shim L Park; Elizabeth F Thompson; Lynne R Wilkens; Yesha Patel; Daniel O Stram; Loic Le Marchand Journal: Carcinogenesis Date: 2014-09-18 Impact factor: 4.944
Authors: Meghan J Chenoweth; Maria Novalen; Larry W Hawk; Robert A Schnoll; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-10 Impact factor: 4.254
Authors: Christopher A Arger; Taraneh Taghavi; Sarah H Heil; Joan Skelly; Rachel F Tyndale; Stephen T Higgins Journal: Nicotine Tob Res Date: 2019-11-19 Impact factor: 4.244
Authors: Kiersten S Derby; Kristine Cuthrell; Christian Caberto; Steven G Carmella; Adrian A Franke; Stephen S Hecht; Sharon E Murphy; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11-24 Impact factor: 4.254
Authors: Lisa Sanderson Cox; Babalola Faseru; Matthew S Mayo; Ron Krebill; Tricia S Snow; Carrie A Bronars; Nicole L Nollen; Won S Choi; Kolawole S Okuyemi; Gary A Salzman; Neal L Benowitz; Rachel F Tyndale; Jasjit S Ahluwalia Journal: Trials Date: 2011-01-25 Impact factor: 2.279
Authors: James W Baurley; Andrew W Bergen; Carolyn M Ervin; Sung-Shim Lani Park; Sharon E Murphy; Christopher S McMahan Journal: BMC Genomics Date: 2022-09-21 Impact factor: 4.547